http://orcid.org/0000-0003-1230-1591
References
- Tienthavorn V, Pattanapongsthorn J, Charoensak S, et al. Prevalence of thalassemia carriers in Thailand. J Hematol Transf Med. 2006;16(4):307–312.
- Premawardhena A, Silver S, Arambepola M, et al. Hemoglobin E-β-thalassemia: progress report from the International Study Group. Ann NY Acad Sci. 2005;1054(1):33–39.
- Fucharoen S, Winichagoon P, Pootrakul P, et al. Variable severity of Southeast Asian β0-thalassemia/Hb E disease. Birth Defects Orig Artic Ser. 1988;23(5A):241–248.
- Winichagoon P, Thonglairoam V, Fucharoen S, et al. Severity differences in β-thalassemia/haemoglobin E syndromes: implication of genetic factors. Br J Haematol. 1993;83(4):633–639.
- Isik P, Yarali N, Tavil B, et al. Endocrinopathies in Turkish children with β thalassemia major: results from a single center study. Pediatr Hematol Oncol. 2014;31(7):607–615.
- Yin XL, Wu ZK, He YY, et al. Treatment and complications of thalassemia major in Guangxi, Southern China. Pediatr Blood Cancer. 2011;57(7):1174–1178.
- Eshragi P, Tamaddoni A, Zarifi K, et al. Thyroid function in major thalassemia patients: is it related to height and chelation therapy? Caspian J Intern Med. 2011;2(1):189–193.
- Sharma R, Seth A, Chandra J, et al. Endocrinopathies in adolescents with thalassaemia major receiving oral iron chelation therapy. Paediatr Int Child Health. 2016;36(1):22–27.
- Fahim FM, Saad K, Askar EA, et al. Growth parameters and vitamin D status in children with thalassemia major in upper Egypt. Int J Hematol Oncol Stem Cell Res. 2013;7(4):10–14.
- Ong CK, Lim SL, Tan WC, et al. Endocrine complications in transfusion dependent thalassaemia in Penang Hospital. Med J Malaysia. 2008;63(2):109–112.
- Giardine B, Borg J, Viennas E, et al. Updates of the HbVar database on human hemoglobin variants and thalassemia mutations. Nucl Acids Res. 2014;42(D1):D1063–D1069.
- Sanguansermsri T, Pape M, Laig M, et al. β0-Thalassemia in a Thai family is caused by a 3.4 kb deletion including the entire β-globin gene. Hemoglobin. 1990;14(2):157–168.
- Viprakasit V. Comprehensive management for thalassemia. J Hematol Transf Med. 2013;23(4):303–320.
- Sripichai O, Makarasara W, Munkongdee T, et al. A scoring system for the classification of β-thalassemia/Hb E disease severity. Am J Hematol. 2008;83(6):482–484.
- Porter J, Viprakasit V. Iron overload. In: Cappellini MD, Cohen A, Porter J, et al., editors. Guidelines for the management of transfusion dependent thalassaemia (TDT). 3rd ed. Nicosia (Cyprus): Thalassaemia International Federation; 2014: 42–97.
- Khadilkar V, Khadilkar A, Arya A, et al. Height velocity percentiles in Indian children aged 5-17 years. Indian Pediatr. 2019;56(1):23–28.
- Trompeter S, Cohen A. Blood transfusion. In: Cappellini MD, Cohen A, Porter J, et al., editors. Guidelines for the management of transfusion dependent thalassaemia (TDT). 3rd ed. Nicosia (Cyprus): Thalassaemia International Federation; 2014: 28–41.
- Mahachoklertwattana P, Chuansumrit A, Sirisriro R, et al. Bone mineral density, biochemical and hormonal profiles in suboptimally treated children and adolescents with β thalassemia disease. Clin Endocrinol. 2003;58(3):273–279.
- Mahachoklertwattana P, Sirikulchayanonta V, Chuansumrit A, et al. Bone histomorphometry in children and adolescents with β-thalassemia disease: in associated focal osteomalacia. J Clin Endocrinol Metab. 2003;88(8):3966–3972.
- Songdej D, Sirachainan N, Wongwerawattanakoon P, et al. Combined chelation therapy with daily oral deferiprone and twice-weekly subcutaneous infusion of desferrioxamine in children with β-thalassemia: 3-year experience. Acta Haematol. 2015;133(2):226–236.
- Shalitin S, Carmi D, Weintrob N, et al. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients. Eur J Haematol. 2005;74(2):93–100.
- Chuansumrit A, Songdej D, Sirachainan N, et al. Safety profile of a liquid formulation of deferiprone in young children with transfusion-induced iron overload: a 1-year experience. Paediatr Int Child Health. 2016;36(3):209–213.